JP2006525328A - 心疾患の治療方法 - Google Patents

心疾患の治療方法 Download PDF

Info

Publication number
JP2006525328A
JP2006525328A JP2006509943A JP2006509943A JP2006525328A JP 2006525328 A JP2006525328 A JP 2006525328A JP 2006509943 A JP2006509943 A JP 2006509943A JP 2006509943 A JP2006509943 A JP 2006509943A JP 2006525328 A JP2006525328 A JP 2006525328A
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutically acceptable
treatment
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525328A5 (cg-RX-API-DMAC7.html
Inventor
ジョン・トーマス・ブラント
ナギー・アルフォンス・ファリッド
ジョゼフ・アンソニー・ジャクボースキー
ケネス・ジョン・ウィンターズ
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2006525328A publication Critical patent/JP2006525328A/ja
Publication of JP2006525328A5 publication Critical patent/JP2006525328A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2006509943A 2003-05-05 2004-04-26 心疾患の治療方法 Pending JP2006525328A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46790303P 2003-05-05 2003-05-05
PCT/US2004/011257 WO2004098713A2 (en) 2003-05-05 2004-04-26 Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4)

Publications (2)

Publication Number Publication Date
JP2006525328A true JP2006525328A (ja) 2006-11-09
JP2006525328A5 JP2006525328A5 (cg-RX-API-DMAC7.html) 2007-01-18

Family

ID=33435139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509943A Pending JP2006525328A (ja) 2003-05-05 2004-04-26 心疾患の治療方法

Country Status (4)

Country Link
US (1) US20060217351A1 (cg-RX-API-DMAC7.html)
EP (1) EP1660183A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006525328A (cg-RX-API-DMAC7.html)
WO (1) WO2004098713A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5363307B2 (ja) * 2007-03-02 2013-12-11 第一三共株式会社 高純度のプラスグレル塩酸塩の製造方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137397B2 (en) * 2004-02-26 2012-03-20 Boston Scientific Scimed, Inc. Medical devices
KR20080016647A (ko) * 2005-06-17 2008-02-21 일라이 릴리 앤드 캄파니 프라수그렐에 대한 투여 계획
JP2009504737A (ja) * 2005-08-19 2009-02-05 イーライ リリー アンド カンパニー 脈管疾患の治療又は予防のためのpar−1/par−4阻害剤の使用
EP2436381A1 (en) * 2006-06-27 2012-04-04 Sandoz AG Crystallization of hydrohalides of pharmaceutical compounds
CA2672134C (en) * 2006-12-07 2015-02-10 Daiichi Sankyo Company, Limited Solid medicinal preparation containing mannitol or lactose
KR101665705B1 (ko) * 2006-12-07 2016-10-12 다이이찌 산쿄 가부시키가이샤 안정성이 개선된 필름 코팅 제제
TWI482641B (zh) 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
WO2008072533A1 (ja) 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited 固形製剤の製造方法
JPWO2008072532A1 (ja) * 2006-12-07 2010-03-25 第一三共株式会社 貯蔵安定性が改善された医薬組成物
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
US20100261908A1 (en) * 2007-11-09 2010-10-14 Dr. Reddy's Laboratories Ltd. Processes for the preparation of prasugrel , and its salts and polymorphs
HU230262B1 (hu) * 2007-11-27 2015-11-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás gyógyszeripari intermedierek előállítására
US20090281136A1 (en) * 2008-05-08 2009-11-12 Sandeep Mhetre Prasugrel pharmaceutical formulations
WO2010094471A1 (en) * 2009-02-17 2010-08-26 Krka, D. D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
PL3100728T3 (pl) 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
JP5795585B2 (ja) * 2009-08-28 2015-10-14 ハーキュリーズ・インコーポレーテッドHercules Incorporated 固体粉末化合物からのフィルムコーティング組成物
EP2275087B8 (en) * 2010-02-22 2012-11-21 Jrs Pharma GmbH+Co.kG Prasugrel controlled release formulations
CN102869668A (zh) 2010-03-09 2013-01-09 斯索恩有限公司 制备普拉格雷的方法
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (en) * 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
CN102775422B (zh) * 2012-03-13 2014-12-31 山东新华制药股份有限公司 普拉格雷中间体的一种晶型
CN102993210A (zh) * 2012-12-19 2013-03-27 苏春华 一种吡啶并噻吩的新化合物
CN104418718B (zh) * 2013-08-28 2018-04-13 山东新时代药业有限公司 一种环丙基‑2‑溴‑2‑(2‑氟苯基)乙酮的制备方法
CN107304216A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049397A1 (en) * 1996-06-26 1997-12-31 Sankyo Company, Limited Novel medicinal compositions of hydropyridines
JPH10120649A (ja) * 1996-08-28 1998-05-12 Sankyo Co Ltd 環状アミン誘導体
JPH11315020A (ja) * 1998-02-27 1999-11-16 Sankyo Co Ltd 環状アミン誘導体を含有する医薬
JP2001131067A (ja) * 1999-08-26 2001-05-15 Sankyo Co Ltd 血小板凝集抑制剤又は動脈硬化進展抑制剤
JP2002145883A (ja) * 2000-07-06 2002-05-22 Sankyo Co Ltd ヒドロピリジン誘導体酸付加塩
WO2002051412A1 (en) * 2000-12-25 2002-07-04 Sankyo Company, Limited Medicinal compositions containing aspirin
JP2002348235A (ja) * 2001-03-23 2002-12-04 Clinical Supply:Kk 再狭窄予防剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
WO2001044239A2 (en) * 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
KR20080021152A (ko) * 2000-07-06 2008-03-06 다이이찌 산쿄 가부시키가이샤 히드로피리딘 유도체 산부가염

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049397A1 (en) * 1996-06-26 1997-12-31 Sankyo Company, Limited Novel medicinal compositions of hydropyridines
JPH10120649A (ja) * 1996-08-28 1998-05-12 Sankyo Co Ltd 環状アミン誘導体
JPH11315020A (ja) * 1998-02-27 1999-11-16 Sankyo Co Ltd 環状アミン誘導体を含有する医薬
JP2001131067A (ja) * 1999-08-26 2001-05-15 Sankyo Co Ltd 血小板凝集抑制剤又は動脈硬化進展抑制剤
JP2002145883A (ja) * 2000-07-06 2002-05-22 Sankyo Co Ltd ヒドロピリジン誘導体酸付加塩
WO2002051412A1 (en) * 2000-12-25 2002-07-04 Sankyo Company, Limited Medicinal compositions containing aspirin
JP2002348235A (ja) * 2001-03-23 2002-12-04 Clinical Supply:Kk 再狭窄予防剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5363307B2 (ja) * 2007-03-02 2013-12-11 第一三共株式会社 高純度のプラスグレル塩酸塩の製造方法

Also Published As

Publication number Publication date
WO2004098713A3 (en) 2004-12-29
US20060217351A1 (en) 2006-09-28
WO2004098713A2 (en) 2004-11-18
EP1660183A2 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
US20060217351A1 (en) Method for treating cardiovascular diseases
EP1728794B1 (en) Maleate addition salt of hydropyridine derivatives
CN101490004B (zh) 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烯基醇的衍生物
EP0017195B1 (en) Derivatives of 2,5-disubstituted-cyclohexane-1,3-diones, process for preparation thereof and pharmaceutical composition containing them
JP2021165298A (ja) ベータ−ラクタマーゼ阻害剤およびその使用
CZ206599A3 (cs) Benzothiofenkarboxamidové deriváty a antagonisty PGD2, které je obsahují
JP2014518260A (ja) 抗血栓症化合物
JPH10182583A (ja) 新規ヒドロキサム酸誘導体
JP2013526488A (ja) シアノ基を含有するチエノピリジンエステル誘導体、その調製方法、使用および組成物
DE69523961T2 (de) Beta-Carbolin Thromboxansynthase Inhibitoren
CN102225940A (zh) 一种苯甲酸异山梨醇酯类化合物、其制备方法及医药用途
WO2011079407A1 (zh) 新的具有抗凝血作用的化合物
JP2514163B2 (ja) ピリミドン誘導体及び類似化合物を含有する、喘息又は炎症性気道疾患の治療用医薬組成物
JP4261639B2 (ja) フェニルイミダゾール系抗高脂血症薬
IE920880A1 (en) Tetronic and thiotetronic acid derivatives
JP2005527518A (ja) 新規なカルコン(chalcone)誘導体とその使用
JPH0430955B2 (cg-RX-API-DMAC7.html)
WO2016206576A1 (zh) 一种氘代噻吩并哌啶衍生物、制备方法及其应用
JPH0379337B2 (cg-RX-API-DMAC7.html)
EP0773019A1 (en) Hyperlipemia remedy
HUT71556A (en) Cyclooxygenase and 5-lipoxygenase inhibiting n(3-biphenylyl-1(s)-methyl-2-propenyl) acetohydroxamic acid derivatives, pharmaceutical compns. contg. them and process to prepare the said compds.
JPS63101322A (ja) トロンボキサンa↓2受容体拮抗剤
JPH06505698A (ja) 新規化合物
JPH0892216A (ja) 含窒素二環性複素環誘導体およびこれを含有する医薬製剤
JP2838282B2 (ja) 血管攣縮治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100630

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100727

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100824